| References: |
Potent TRPM8 antagonist (IC50 values are 5.3 and 8.3 nM for rat and human channels respectively). Exhibits >350-fold selectivity for TRPM8 over TRPV4, TRPV1 and TRPA1. Reduces HSC3 and HSC4 oral squamous carcinoma cell migration and invasion in vitro. Also attenuates icilin-induced wet dog shakes in rats. Orally active. For the detailed information of RQ-00203078, the solubility of RQ-00203078 in water, the solubility of RQ-00203078 in DMSO, the solubility of RQ-00203078 in PBS buffer, the animal experiment (test) of RQ-00203078, the cell expriment (test) of RQ-00203078, the in vivo, in vitro and clinical trial test of RQ-00203078, the EC50, IC50,and affinity,of RQ-00203078, For the detailed information of RQ-00203078, the solubility of RQ-00203078 in water, the solubility of RQ-00203078 in DMSO, the solubility of RQ-00203078 in PBS buffer, the animal experiment (test) of RQ-00203078, the cell expriment (test) of RQ-00203078, the in vivo, in vitro and clinical trial test of RQ-00203078, the EC50, IC50,and affinity,of RQ-00203078, Please contact DC Chemicals. |
